Skip to content
lifestyle.hungrybear.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Propanc Biopharma, Inc.
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
June 16, 2026
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
June 11, 2026
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
May 15, 2026
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
May 13, 2026
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
March 24, 2026
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
March 12, 2026
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
March 10, 2026
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
March 3, 2026
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
February 18, 2026
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
February 11, 2026
1
2
Next Page
→